Celcuity, Inc. (NASDAQ:CELC) Stock Has Consensus Target Price of $152.57

Shares of Celcuity, Inc. (NASDAQ:CELC) have received a consensus rating of “Moderate Buy” from the fifteen research firms that are presently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell rating and thirteen have issued a buy rating on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $152.57.

CELC has been the topic of a number of recent analyst reports. Citizens Jmp reiterated a “market outperform” rating and issued a $177.00 price objective on shares of Celcuity in a report on Monday, August 17th. Cantor Fitzgerald began coverage on Celcuity in a research note on Thursday, October 22nd. They set an “overweight” rating and a $140.00 target price for the company. Stifel Nicolaus decreased their target price on Celcuity from $175.00 to $150.00 and set a “buy” rating for the company in a research note on Friday, August 14th. TD Cowen reaffirmed a “buy” rating and issued a $145.00 price target on shares of Celcuity in a report on Wednesday, October 21st. Finally, Citigroup reaffirmed a “market outperform” rating on shares of Celcuity in a report on Monday, October 19th.

Institutional Trading of Celcuity

Institutional investors have recently modified their holdings of the stock. Assenagon Asset Management S.A. lifted its position in shares of Celcuity by 685.9% during the 3rd quarter. Assenagon Asset Management S.A. now owns 1,478,607 shares of the company’s stock worth $117,579,000 after buying an additional 1,290,466 shares during the last quarter. Bank of America Corp DE acquired a new position in shares of Celcuity in the 2nd quarter valued at $153,928,000. Wellington Management Group LLP grew its position in shares of Celcuity by 111.4% in the 2nd quarter. Wellington Management Group LLP now owns 906,595 shares of the company’s stock valued at $94,848,000 after buying an additional 477,643 shares during the last quarter. Jennison Associates LLC grew its position in shares of Celcuity by 0.6% in the 1st quarter. Jennison Associates LLC now owns 231,140 shares of the company’s stock valued at $26,382,000 after buying an additional 1,436 shares during the last quarter. Finally, Alyeska Investment Group L.P. grew its position in shares of Celcuity by 127.2% in the 2nd quarter. Alyeska Investment Group L.P. now owns 170,846 shares of the company’s stock valued at $17,874,000 after buying an additional 95,664 shares during the last quarter. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Celcuity Stock Up 0.8%

Celcuity stock opened at $65.80 on Tuesday. Celcuity has a 1-year low of $53.54 and a 1-year high of $151.02. The company has a debt-to-equity ratio of 6.04, a current ratio of 8.93 and a quick ratio of 8.93. The stock has a market cap of $3.22 billion, a PE ratio of -15.30 and a beta of 0.10. The stock’s fifty day moving average is $79.55 and its two-hundred day moving average is $101.12.

Celcuity (NASDAQ:CELC) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.16) by ($0.28). On average, sell-side analysts expect that Celcuity will post -4.98 EPS for the current fiscal year.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company developing functional diagnostic tests designed to help identify cancer treatments that may be most effective for individual patients. Its technology analyzes living tumor cells taken from patients to measure how signaling pathways respond to different therapies, with the goal of supporting more personalized treatment decisions.

The company’s CELsignia platform is designed to assess the activity of cancer-related signaling pathways in patient-derived cells.